 Up to eightfold therapeutic doses have been given in studies without problems.Rolapitant moderately inhibits the liver enzyme CYP2D6.Blood plasma concentrations of the CYP2D6 substrate dextromethorphan have increased threefold when combined with rolapitant; and increased concentrations of other substrates are expected.